Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 81-86, January 2009

The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer

  • Martin Gleave, M.D.

      Affiliations

    • Department of Urology, Vancouver General Hospital, University of British Columbia, Vancouver, Canada
    • ,
  • Laurence Klotz, M.D.

      Affiliations

    • Division of Urology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada
    • ,
  • Samir S. Taneja, M.D.

      Affiliations

    • Division of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, NY 10016, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-646-825-6321; fax: +1-646-825-6399

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1078-1439(08)00183-X

doi:10.1016/j.urolonc.2008.07.025

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 81-86, January 2009

Article Tools